#Obinutuzumab
LightNews LightNews
kidneystories.bsky.social
The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey ... - goo.gl/alerts/iLzkU2 #GoogleAlerts
The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD | Rheumatology Live
Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.
goo.gl
January 14, 2026 at 10:43 AM
kireports.bsky.social
Prospective Cohort Study of #Obinutuzumab in Rituximab-Resistant Primary #Membranous Nephropathy

#VisualAbstract by Denisse Arellano

https://www.kireports.org/article/S2468-0249(25)00746-6/fulltext
January 9, 2026 at 2:01 PM
vcclibrary.bsky.social
NICE Technology Appraisal Guideline [TA1119]: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. www.nice.org.uk/guidance/ta1...
Overview | Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | Guidance | NICE
www.nice.org.uk
January 9, 2026 at 10:14 AM
updates.chemo.org.uk
🤖 Automated message

8 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2026-01-08.html

Changes: obinutuzumab, sacituzumab govitecan, fedratinib dihydrochloride monohydrate, imlifidase, abemac...
Updated Summary of Product Characteristics – Chemotherapy Updates
Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.
updates.chemo.org.uk
January 8, 2026 at 3:23 PM
leukaemiauk.bsky.social
A fantastic start to the year! Venetoclax with obinutuzumab has been approved on the NHS in England for people with untreated CLL, expanding access to a fixed-duration, targeted first-line treatment option. 👏
An orange graphic which reads, ‘New treatment for chronic lymphocytic leukaemia in England: Venetoclax with obinutuzumab’ followed by ‘Approved’ with a green tick symbol.
January 8, 2026 at 11:32 AM
arthritisaustralia.bsky.social
The PBAC is considering funding Obinutuzumab for class III/IV lupus nephritis. Share how the condition & current treatments affect you, & what a new option would mean.
Email: [email protected]
More info and to make a personal submission: ohta-consultations.health.gov.au/ohta/pbac-ma...
January 8, 2026 at 12:00 AM
onclive.bsky.social
Obinutuzumab/Zanubrutinib/Pomalidomide/Venetoclax Quadruplet Is Effective in High-Risk #MCL @ash.hematology.org #ASH25 #hematology

www.onclive.com/view/obinutu...
Obinutuzumab/Zanubrutinib/Pomalidomide/Venetoclax Quadruplet Is Effective in High-Risk MCL | OncLive
Obinutuzumab plus zanubrutinib, pomalidomide, and venetoclax produced high response rates in high-risk MCL.
www.onclive.com
January 7, 2026 at 2:20 PM
onclive.bsky.social
Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive #CLL
@mdanderson.bsky.social #oncology

www.onclive.com/view/late-ad...
Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive CLL | OncLive
Mahesh Swaminathan, MB, BS, discusses whether the addition of obinutuzumab after 1 year of acalabrutinib/venetoclax is safe and effective in CLL.
www.onclive.com
January 6, 2026 at 8:06 PM
updates.chemo.org.uk
🤖 Automated message

6 cancer treatment summary of product characteristics have been updated recently.

https://updates.chemo.org.uk/news/SPC_updates_2026-01-05.html

Changes: mycophenolate mofetil, paclitaxel albumin, talquetamab, obinutuzumab, sacituzumab govitecan
Updated Summary of Product Characteristics – Chemotherapy Updates
Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.
updates.chemo.org.uk
January 5, 2026 at 3:23 PM
deceraclinicaledu.bsky.social
New ASH 2025 analysis: CLL17 (Phase III)
Fixed-duration venetoclax + obinutuzumab or venetoclax + ibrutinib showed noninferior PFS vs continuous ibrutinib in untreated CLL.
Slideset 👉 https://bit.ly/3XW6Qdu

#CLL #Hematology
CLL17: Phase III Trial of Continuous Ibrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab or Venetoclax Plus Ibrutinib for Untreated CLL
Data from the phase III CLL17 study demonstrate noninferior PFS with fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib vs continuous ibrutinib among patients with untreated CLL ...
deceraclinical.com
December 26, 2025 at 9:20 PM
ashclinicalnews.bsky.social
Compared with #obinutuzumab monotherapy, the next-gen BTK inhibitor #zanubrutinib in combination with #obinutuzumab led to improved survival in patients with #FollicularLymphoma, resulting in ORRs of 70.3% vs. 44.4% and PFS of 22.1 vs. 10.3 months: https://ow.ly/qzV250XMMvj
#HemeSky #MedSky
December 23, 2025 at 4:05 PM
dgfn.bsky.social
NEJM study on lupus nephritis: Obinutuzumab in addition to standard therapy led to complete renal remission more often than standard therapy alone. Lupus nephritis is a serious kidney disease with a risk of CKD and kidney failure.
#Nephrology #CKD
December 19, 2025 at 11:23 AM
vasculitides.bsky.social
A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
ClinicalTrials.gov
clinicaltrials.gov
December 15, 2025 at 6:14 PM
rheumnow.bsky.social
Roche announced that the European Commission has approved obinutuzumab (Gazyvaro in EU/UK & Gazyva in US) in combination with mycophenolate mofetil for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis. checkorphan.org/news/europea...
European Commission Approves Roche’s Gazyva/Gazyvaro for Adults with Active Lupus Nephritis – CheckOrphan
checkorphan.org
December 12, 2025 at 4:00 PM
ashclinicalnews.bsky.social
#ASH25 The BCL2 inhibitor #sonrotoclax produced good responses in patients with treatment-naïve CLL/SLL when combined with #obinutuzumab, with ORRs of 89% across all patients and 93% at a 320 mg dose: https://ow.ly/M8uB50XF6zT
#HemeSky #MedSky
December 8, 2025 at 2:30 PM
danafarber.bsky.social
Austin Kim, MD, presents results from the phase 1/2 MAVO study evaluating acalabrutinib + venetoclax + obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma.
#ASH25
December 7, 2025 at 10:18 PM
wcmenglanderipm.bsky.social
Great new paper in Blood Advances, "MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma," by our EIPM Directior Olivier Elemento, PhD and colleagues.

Learn more: ashpublications.org/bloodadvance...
December 2, 2025 at 7:41 PM
wcmcpathology.bsky.social
New in Blood Advances, "MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab or Obinutuzumab for Mantle Cell Lymphoma," by WCM's Dr. Jia Ruan with Pathology and Laboratory Medicine department Drs. Giorgio Inghirami and Selina Chen-Kiang!

ashpublications.org/bloodadvance...
December 2, 2025 at 7:16 PM
rarediseaseadvisor.bsky.social
Venetoclax–obinutuzumab (#VenObi) demonstrated durable disease control with partial but steady immune restoration through 48 months. @ash.hematology.org

Read more: https://bit.ly/482ZHOf

#RareDisease #ChronicLymphocyticLeukemia #CLL #Hematology
Sustained CLL Clearance With Ven-Obi Supports Durable Immune Recovery
Fixed-duration venetoclax–obinutuzumab sustained chronic lymphocytic leukemia (CLL) cell depletion while permitting measured immune recovery.
bit.ly
November 28, 2025 at 3:05 PM
ped-neph.bsky.social
B-cell-depleting agents like rituximab (RTX) treat severe steroid-dependent idiopathic nephrotic syndrome (SDNS) & frequent relapses. Read this Original Article on obinutuzumab as an option for SDNS children resistant to RTX w/anti-RTX antibodies.
link.springer.com/article/10.1...
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies
November 26, 2025 at 7:10 PM
renalurologynews.bsky.social
An analysis of kidney biopsies before and after obinutuzumab treatment of lupus nephritis showed histologic remission or near remission in a greater proportion of patients than had complete renal response in the REGENCY trial.
www.renalandurologynews.com/reports/lupu... #KidneyWk #KidneyCare
Obinutuzumab Can Achieve Histologic Remission in Lupus Nephritis - Renal and Urology News
Investigators analyzed biopsy histology from a subset of patients with lupus nephritis treated with obinutuzumab vs placebo in the phase 3 REGENCY trial
www.renalandurologynews.com
November 17, 2025 at 3:59 PM
lupusencyclopedia.bsky.social
😍 I LOVE the @EULAR guidelines for 1st-line therapy for LN! If everyone did this IMMEDIATELY (include a CNI, obinutuzumab, or belimumab) instead of just mycophenolate or CYC with steroids, greater numbers of patients would go into renal remission & fewer to end stage renal disease! #SLE #lupus
November 15, 2025 at 5:48 PM
jostflynnmd.bsky.social
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies
rdcu.be/ePZBl
November 14, 2025 at 8:58 PM
mari-19.bsky.social
FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis
www.lupus.org/news/fda-app...
@lupus.org
FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis
The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease...
www.lupus.org
November 13, 2025 at 3:48 PM
rheumnow.bsky.social
Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. www.businesswire.com/news/home/20...
ClinicalTrials.gov
Study record managers: refer to the Data Element Definitions if submitting registration or results information.
ClinicalTrials.gov
November 11, 2025 at 6:38 PM